Haematopoietic stem cells (HSCs) are self-renewing cells that sustain the production of all blood and immune cell lineages throughout life by residing at the top of the haematopoietic hierarchy. They first arise early in embryogenesis and their site of action changes during development. In adult mammals, HSCs reside in the bone marrow within a complex microenvironment termed the HSC niche (1) . They are defined by their ability to completely repopulate the entire blood system of a recipient, resulting in the formation of red blood cells, megakaryocytes, myeloid cells and lymphocytes, and in order to do this they are able to undergo asymmetric division where one daughter cell remains as a HSC whilst the other becomes committed to differentiation (2) . In the bone marrow, to prevent exhaustion and to preserve their ability to self-renew, HSCs are normally maintained in a dormant or quiescent state, from which they can be rapidly awakened in response to haematological stress (3) . How this is regulated is an important issue and in a recent issue of Cell Stem Cell Karigane et al have shed new light on how the p38 MAPK pathway promotes stressinduced proliferation in HSCs (4) .
HSCs are maintained in quiescence through tight regulation of their metabolic state, which is controlled by both cell intrinsic and extrinsic factors. Long-term HSCs (LT-HSCs) keep rates of energy consumption low through anaerobic glycolysis, resulting in low levels of reactive oxygen species (ROS) production (5). Maintaining minimal levels of ROS is thought to be key for maintaining the selfrenewing capacity of stem cells and preventing HSC exhaustion (6) . ROS production is limited in quiescent HSCs through the actions of hypoxia inducible factor 1a (HIF1a), which drives cellular metabolism towards anaerobic glycolysis instead of mitochondrial respiration (6, 7) . HIF1a controls the activation of pyruvate dehydrogenase kinase 2 (Pdk2) and Pdk4, which maintain glycolysis whilst actively suppressing mitochondrial metabolism in quiescent HSCs (5) .
Understanding the metabolic changes that underlie the switch from quiescence to proliferation could not only help to improve the methods and protocols for expanding and maintaining HSCs in vitro to prevent HSC exhaustion, but could also inform on how alterations in these cells underlie the development of stem cell diseases such as leukaemias (8) . As quiescent cells have different energy requirements to active cells, changes in cellular metabolism are thought to be important in the transition from dormancy to cycling. This is reflected by the observation that whilst ROS levels are kept low in quiescent cells, elevating ROS production promotes HSC differentiation to enable repopulation (6).
The p38α MAPK pathway has been suggested to act downstream of ROS in HSCs (9, 10) . p38 MAPKs form a subgroup of MAPKs, of which 4 isoforms exist in mammalian cells and of which p38α has been the most intensely studied. Interest in p38a in immunity was first stimulated by the finding that it was the cellular target of a group of pyridinyl imidazole drugs, such as SB203580, that could inhibit TNF production, however since then a wide variety of functions for p38α have been uncovered (11, 12) . In mice, p38a knockout is embryonic lethal due to problems with extraembryonic and placental development, impacting on cardiovascular development in the embryo (13, 14) . Rescue of the extra-embryonic issues allowed p38a embryos to develop until term. One knockout study additionally reported an issue with erythropoiesis, however this was not cell autonomous as HSCs from these mice could restore haematopoietic development in recipient mice (15) . Together these results suggest that p38a is not critical for HSC development and homeostasis.
Several studies have however indicated roles for p38a in HSCs following stress. Treatment of HSCs in culture with buthione sulfoximine (BSO) to induce ROS production leads to activation of p38 and was linked to a decreased ability to maintain HSC quiescence (9) . Significantly, mice with null mutations in ATM, Jak2 or FOXO3a show elevated levels of ROS in their HSC populations leading to a decreased repopulation capacity of these HSCs in adoptive transfer experiments in mice (9,10,16).
The elevated ROS levels were linked to increased p38 activation, and long term treatment of the mice with SB203580 (which inhibits p38a and p38b) in vivo was able to restore the capacity of these HSCs to repopulate the HSC compartment in lethally irradiated mice (9, 10) . To investigate if p38α also played a similar role in wild type HSCs, serial transfer of LSK cells was used. In these experiments strong elevations in ROS were only apparent after the 3 rd transfer, and this correlated to increased to p38α activation and a reduction in the capacity of the cells to repopulate the HSC compartment (9) . Together these results suggest that when HSCs are exposed to high levels of ROS, p38α activation has a negative effect on the capacity of cells to maintain an HSC phenotype.
p38α is however activated in response to many other stimuli in addition to ROS and it is possible that it may have different functions in HSCs depending on the context or upstream stimuli. An early indication that this might be the case came from studies on the p38α activated kinase MK2, where bone marrow or LSK cells from mice deficient in MK2 showed a reduced capacity to repopulate the bone marrow relative to wild type cells (17) . Work by Karigane et al has now uncovered a new mechanism by which p38 MAPK signalling regulates HSC metabolism in response to haematological stress, under conditions that are unlikely to be driven by ROS (4) . In a series of experiments, they reveal a novel p38α dependent pathway that regulates the metabolic status of HSCs and promotes cellular proliferation via activating purine metabolism. After initially identifying p38α as the major p38 MAPK isoform expressed in HSCs, they analysed haematopoietic phenotypes in an inducible conditional p38α mouse knockout model. Global deletion of p38α induced by intra-peritoneal injection of tamoxifen was found to be ~99% effective in HSCs compared to wild-type controls, and A key question is how p38 regulates Mitf transcripts in HSCs, as p38 is known to regulate both transcription and mRNA stability. In melanocytes, p38 has been reported to upregulate Mitf transcription via the transcription factor CREB (19, 20 Intriguingly Mitf has been found to be activated by p38α in osteoclasts via phosphorylation on serine 307 (24) although the relevance of this in HSCs remains to be determined.
Taken together, the elegant experiments reported by Karigane and co-workers describe a key role for a p38α-Mitf pathway in regulating purine metabolism and proliferation in response to haematopoietic stress, and highlight the importance of understanding how metabolic changes relate to HSC function. Whilst this work extends our knowledge of the dynamic roles of p38α in HSCs, a greater understanding of the mechanisms by which p38α is activated in response to haematological stress along with further details of exactly how p38α regulates Mitf in these cells is likely to lead to more efficient strategies to harness this pathway for therapeutic benefit. Given the recent identification of Mitf as a novel gene target regulated by treatment with the HIV protease inhibitor nelfinavir (25) it will be exciting to see whether modulating Mitf expression is a viable approach for manipulating HSCs during ex-vivo expansion or during leukaemia chemotherapy.
